Spruce Biosciences closed at $46.61 on Nov 4, up 8.88%, 63.3% below its 52-week closing high. Volume of 52.0K shares was 0.66× its 20-day average (below normal).
Split-adjusted performance: +8.9% over one month, -19.5% over six months, -55.5% over one year.
Short interest was 522.1K shares at the Oct 15 settlement, up 21.0% from the prior report (22.4% of float, 6.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SPRBSpruce Biosciences | $46.61 | +8.88% | −19.5% | — | — | — | $134.0M | |
| DERMJourney Medical | $4.73 | +1.94% | −9.2% | +18.9% | −1.7% | — | $133.5M | Compare |
| PYXSPyxis Oncology | $1.66 | +1.22% | −27.8% | −100.0% | — | — | $138.5M | Compare |
| YARWYarrow Bioscience | $14.91 | −18.84% | — | — | — | — | $125.8M | Compare |
| FHTXFoghorn Therapeutics | $2.10 | −1.41% | −55.1% | +112.7% | −44.7% | — | $124.7M | Compare |
| CUECue Biopharma | $19.84 | −4.89% | −41.6% | +166.7% | −1943.2% | — | $144.1M | Compare |
| NKTXNkarta | $1.73 | +13.07% | −47.9% | — | — | — | $123.9M | Compare |
| NERVMinerva Neurosciences | $2.57 | +9.36% | −58.7% | — | — | — | $122.7M | Compare |
| MGNXMacroGenics | $2.31 | −0.86% | −23.3% | +378.0% | 59.4% | — | $147.1M | Compare |
No recent articles focused on Spruce Biosciences. 1 articles mention it in passing.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
